Of note, TPBCs showed significantly lower rates of ERBB2 and MYC amplification than ER-PR-HER2+ breast cancers (ERBB2: 53% vs. 85%, P = 0.001; MYC: 24% vs. 47%, P = 0.013). This evidence concerns the gene MYC and breast carcinoma.